NASDAQ: HUMAHumacyte Inc Stock
$1.47-0.03 (-2%)
Updated Sep 12, 2025
HUMA Price
$1.47
Fair Value Price
$0.24
Market Cap
$232.81M
52 Week Low
$1.15
52 Week High
$6.77
P/E
-3.27x
P/B
57.45x
P/S
397.14x
PEG
N/A
Dividend Yield
N/A
Revenue
$818.00k
Earnings
-$58.66M
Gross Margin
56%
Operating Margin
-5,888.75%
Profit Margin
-7,171.3%
Debt to Equity
33.25
Operating Cash Flow
-$104M
Beta
1.44
Next Earnings
Nov 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
HUMA Overview
Humacyte, Inc. develops and manufactures off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company uses its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Humacyte is developing a portfolio of HAVs targeting the vascular repair, reconstruction, and replacement market, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery. The company was founded in 2004 and is headquartered in Durham, NC.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine HUMA's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
HUMA
Ranked#409 of 476
Ranked#409 of 476
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.30 | A | |
| $37.96 | A | |
| $7.91 | A |
Be the first to know about important HUMA news, forecast changes, insider trades & much more!
HUMA News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HUMA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HUMA ($1.47) is overvalued by 513.25% relative to our estimate of its Fair Value price of $0.24 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
HUMA ($1.47) is not significantly undervalued (513.25%) relative to our estimate of its Fair Value price of $0.24 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
HUMA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more HUMA due diligence checks available for Premium users.
Valuation
HUMA fair value
Fair Value of HUMA stock based on Discounted Cash Flow (DCF)
Price
$1.47
Fair Value
$0.24
Overvalued by
513.25%
HUMA ($1.47) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
HUMA ($1.47) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
HUMA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
HUMA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.27x
Industry
-97.08x
Market
36.98x
HUMA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
57.45x
Industry
4.65x
HUMA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HUMA's financial health
Profit margin
Revenue
$301.0k
Net Income
-$37.7M
Profit Margin
-12,511%
HUMA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
HUMA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$138.8M
Liabilities
$134.7M
Debt to equity
33.25
HUMA's short-term assets ($51.73M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HUMA's long-term liabilities ($113.66M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HUMA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$26.4M
Investing
-$568.0k
Financing
$2.2M
HUMA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
HUMA vs Biotech Stocks
Humacyte Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.